Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis

Baglama, Špela Šuler; Peteln, Irena; Jemec, Gregor B E

doi:10.1080/09546634.2022.2131298

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, oxidative stress can also alter the nuclear factor kappa B pathway, thus supporting the role of bortezomib in the inflammation of AK 17. Interestingly, Šuler Baglama et al have described that chemotherapy-induced inflammation can partially or completely cure AK in up to 96.4% of patients, a finding which postulates the role of taxanes, pemetrexed and doxorubicin in the management of AK 18…”

Section: Discussionmentioning

confidence: 93%

Inflammation of actinic keratosis from chemotherapy in a relapsed multiple myeloma patient

Khan,

Micho Ulbeh,

Zonder

et al. 2023

BMJ Case Rep

View full text Add to dashboard Cite

A man in his 60 s with a history of actinic keratosis (AK) and relapsed IgG kappa multiple myeloma (MM) recently received VD-PACE (bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) chemotherapy and presented with numerous haemorrhagic, scaly lesions on his scalp and face. He also had sepsis from methicillin-sensitiveStaphylococcus aureus(MSSA) bacteraemia. Since the lesions were only present in the areas of pre-existing AK, a diagnosis of inflammation of AK secondary to chemotherapy was made. Sepsis was treated with appropriate antibiotics, and inflammation of AK was managed with topical steroids, leading to complete recovery.

show abstract

Section: Discussionmentioning

confidence: 93%